Ocular Inflammation With Presence of Risk of Infection
In a preclinical study, increased viscosity improved ocular retention and bioavailability. The XanGen® formulation of TOBRADEX® ST creates a unique interaction with tears that increases the viscosity of each drop to provide longer ocular retention on the eye and increased ocular bioavailability of the drug without causing visual blurriness.1,2
After 1 week of TOBRADEX® ST dosing, patients had >50% reduction in symptoms. This was demonstrated in a preclinical study utilizing a rabbit model that closely mimics the human eye.3
Eyevance® Pharmaceuticals LLC has been acquired by Santen Pharmaceutical Co., Ltd. TobraDex® ST is a registered trademark of Eyevance Pharmaceuticals. All other trademarks are the property of their respective owners.
- TOBRADEX® ST Suspension [package insert]. Fort Worth, TX: Eyevance Pharmaceuticals LLC; 2011.
- Scoper SV, Kabat AG, Owen GR, et al. Ocular distribution, bactericidal activity and settling characteristics of TOBRADEX® ST ophthalmic suspension compared with TobraDex® ophthalmic suspension. Adv Ther. 2008;25(2):77-88.
- Torkildsen GL, Cockrum P, Meier E, et al. Evaluation of clinical efficacy and safety of tobramycin/dexamethasone ophthalmic suspension 0.3%/0.05% compared to azithromycin ophthalmic solution 1% in the treatment of moderate to severe acute blepharitis/blepharoconjunctivitis. Curr Med Res Opin. 2011;27(1):171-178.